Mendelian Randomization Analysis Identifies Body Mass Index and Fasting Insulin as Potential Causal Risk Factors for Pancreatic Cancer Risk
Menée à partir d'une méthode de randomisation mendélienne et de données portant sur 7 110 patients atteints d'un cancer du pancréas et sur 7 264 témoins, cette étude évalue l'association entre l'indice de masse corporelle, des facteurs métaboliques, un diabète de type 2 et le risque de cancer du pancréas
In this issue of the Journal, Carreras-Torres and colleagues present evidence for a potential causal role of body mass index (BMI) and fasting insulin with risk of pancreatic cancer in 7110 cases and 7264 controls (1). Specifically, genetically increased levels of BMI and fasting insulin were associated with an increased risk of pancreatic cancer; the association with fasting insulin was limited to men. No evidence of a causal association was observed for type II diabetes, fasting glucose, glucose at two hours postchallenge, height, waist-to-hip circumference ratio, and four lipids (eg, total cholesterol, high- and low-density lipoprotein cholesterol, and triglycerides).
JNCI: Journal of the National Cancer Institute , éditorial, 2016